Suudi Arabistan - İngilizce - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

human bioplazma llc, hungary - albumin human - solution - 20 %

ABD - İngilizce - NLM (National Library of Medicine)

kedrion s.p.a - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin (human) 12.5 g in 50 ml - for restoration and maintenance of circulating blood volume where volume deficiency is demonstrated and colloid use is appropriate. kedbumin® is indicated for severe albumin deficiency caused by illness or active bleeding. when albumin deficiency results from excessive protein loss, the effect of albumin administration will be temporary unless the underlying disorder is reversed. kedbumin® is indicated for maintenance of cardiovascular function following the removal of large volumes of ascitic fluid due to cirrhosis [1, 2]. kedbumin® is indicated as a plasma expander in the fluid management of severe forms of ovarian hyperstimulation syndrome (ohss) [3, 4]. kedbumin® is indicated in conjunction with diuretics to correct fluid volume overload associated with ards [5]. kedbumin® is indicated after > 24 hours post burn in patients experiencing severe albumin depletion in order to favor edema re-absorption [6]. kedbumin® is indicated in patients undergoing long term dialysis or for those patients who are fl

Malta - İngilizce - Medicines Authority

baxter healthcare limited - albumin, human 50 g/l - solution for infusion

Malta - İngilizce - Medicines Authority

baxter healthcare limited - albumin, human 200 g/l - solution for infusion

Singapur - İngilizce - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - human albumin - solution, sterile - 200 mg/ml - human albumin 200 mg/ml

Singapur - İngilizce - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - albumin (human serum) (venous) - injection - 5.00% - albumin (human serum) (venous) 5%

Singapur - İngilizce - HSA (Health Sciences Authority)

csl behring pte. ltd. - human albumin - infusion, solution - 200g/l - human albumin 200g/l

Singapur - İngilizce - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - albumin (human serum) (venous) - infusion, solution - 0.2 g/ml - albumin (human serum) (venous) 0.2 g/ml

ABD - İngilizce - NLM (National Library of Medicine)

ge healthcare inc. - human albumin microspheres (unii: t8c6w1n6nw) (human albumin microspheres - unii:t8c6w1n6nw), perflutren (unii: ck0n3wh0sr) (perflutren - unii:ck0n3wh0sr) - human albumin microspheres 10 mg in 1 ml - optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders. do not administer optison to patients with known or suspected hypersensitivity to perflutren or albumin [see warnings and precautions (5.5)] . risk summary there are no data with optison use in pregnant women to inform any drug-associated risks. no adverse developmental outcomes were observed in animal reproduction studies with intravenous administration of optison to pregnant rats and rabbits during organogenesis at doses up to at least 5 and 10 times the recommended human dose based on body surface area (see data ). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data optison was administered intravenously to rats at doses of 0.25, 5 and 10 ml/kg/day (approximately 0.2, 5 and 10 times the recommended maximum human dose of 8.7 ml, respectively, based on body surface area) and to rabbits at 0.25, 2.5 and 5 ml/kg/day (approximately 0.5, 5 and 10 times the recommended maximum human dose, respectively, based on body surface area) during organogenesis. no significant findings attributable solely to a direct effect on the fetus were detected in the studies. there are no data on the presence of perflutren protein-type a microspheres in human milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for optison and any potential adverse effects on the breastfed infant from optison or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. of the total number of subjects in a clinical study of optison, 35% were 65 and over, while 14% were 75 and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Belçika - İngilizce - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxalta innovations gmbh - albumin human 50 g/l - solution for infusion - 50 g/l - albumin human 50 mg/ml - albumin